13 November 2023 - If approved, momelotinib will become the first and only treatment in the EU specifically indicated for myelofibrosis patients with moderate to severe anaemia.
GSK today announced the CHMP of the EMA has adopted a positive opinion recommending approval of momelotinib for the treatment of disease-related splenomegaly or symptoms in adult patients with moderate to severe anaemia who have primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis and who are Janus kinase inhibitor naïve or have been treated with ruxolitinib.